Pretargeted immuno-PET was then studied in the clinic for several cancers known to express CEA: breast cancers (Schoffelen et al. 2010), colorectal carcinoma and medullary thyroid cancers (Kraeber-Bodéré et al. 2015). Here, CEACAM5 is linked to medullary thyroid gland carcinoma.